INTRODUCTION

Since the introduction of highly active antiretroviral therapy (HAART) as the standard treatment for human immunodeficiency virus (HIV) or AIDS, marked improvement in survival has been seen in people with HIV or AIDS (PWHA) (1-8). Cancer is an important cause of morbidity and mortality in PWHA, but the patterns of cancer after the establishment of HAART is changing (9-13). Three decades ago when HAART was not well established, opportunistic cancers, known as AIDS-defining cancers (ADCs) such as Kaposi’s sarcoma, non-Hodgkin’s lymphoma, and cervical cancer were the most common types of cancers. However, since the introduction of HAART in 1996, rates of ADCs have decreased dramatically (14,15). On the other hand, the burden of non-AIDS-defining cancers (NADCs) is increasing, accompanied by improved survival rates of PWHA (10).

The incidence of NADCs is higher in PWHA than in the general population (10,15,16). In addition to higher incidence, NADCs in PWHA usually progresses more aggressively, is detected at a later stage, and recurs more frequently; PWHA have a worse prognosis than similar staged non-HIV-infected patients with the same cancers (17,18). The type of malignancy and incidence of NADCs differs between countries, the difference mainly due to the genetics and socio-economic characteristics of the citizens (9,15,19). It is important to make an appropriate screening plan for the early detection and early treatment of NADCs in PWHA. Therefore, we need to have information about trends of the common types and characteristics of cancers in Korean HIV-infected patients. Cancer epidemiology in Korean PWHA has not been studied since 2007 when 2 studies investigated trends of cancer in Korean PWHA (20,21). The objective of this study was to investigate recent trends of cancer in Korean PWHA.

MATERIALS AND METHODS

Study design

A descriptive epidemiology study was conducted to assess the trend of malignancies among PWHA in Korea. All PWHA who visited Pusan National University Hospital from 2000 to 2014 were included in the study. Pusan National University Hospital...
is a 1,220 bed, university-affiliated teaching hospital and provides HIV care for PWHA in the southeastern area of Korea. Patients below 15 years of age who had no follow-up after their first visit were excluded. Patients who were diagnosed with cancer at least 3 years before diagnosis of HIV were excluded (9). The observation period for individual patients was from the first visit to the date of diagnosis of any cancer; death; transfer to another institute; or December 31, 2014. Demographical, epidemiological, and clinical data were obtained by a retrospective review of medical records. AIDS-defining illness and clinical categories were defined by the 1993 Centers for Disease Control and Prevention (CDC) classification criteria (22). Cancer was defined as such if the diagnosis of cancer was confirmed by histological examinations. Multiple diagnoses of cancers were allowed for a patient if the primary site of cancers were different. Kaposi’s sarcoma, non-Hodgkin’s lymphoma, and cervical cancer were categorized as ADCs, and all other types of cancers were categorized as NADCs according to the CDC classification criteria. To evaluate the trends in malignancies, we divided the overall observation period into 3 periods (period 1, 2000–2004; period 2, 2005–2009; period 3, 2010–2014) to observe how trends of cancer change every 5 years.

Statistical analysis
IBM SPSS statistics version 22, (IBM, Armonk, NY, USA) was used for all statistical analyses. Categorical variables were compared using Pearson’s χ² test or Fisher’s exact test, whereas non-categorical variables were tested using the Mann-Whitney U-test or Kruskal Wallis test. Poisson regression was used to compare incidence rates according to periods. All tests of significance were 2-tailed; P < 0.05 was considered to be significant.

Ethics statement
The present study protocol was reviewed and approved by the Institutional Review Board of Pusan National University Hospital (IRB No. 1704-003-053). Informed consent was waived by the board.

RESULTS

Characteristics of the patients
Nine hundred and fifty PWHA were enrolled into this study. Mean age of the patients was 42.4 ± 11.8 years; 836 (88%) were male and 378 (39.8%) were homosexual. The most common mode of transmission was sexual contact (94.2%), and only 13 patients (1.4%) had an intravenous drug use history. Mean CD4+ T cell count was 250 ± 220.9 cells/μL. Four hundred and fifty-nine patients (48.3%) had progressed to AIDS and 432 patients (45.5%) had CD4+ T cell counts of less than 200 when they were diagnosed with HIV infection.

Trends of cancer in PWHA
Nine hundred and fifty PWHA were observed for a total of 4,439.71 person-years and 48 episodes (5.05%) of cancer were diagnosed in 47 patients. Cancer incidence among PWHA was 10.8 (95% confidence interval [CI], 8.0–14.3)/1,000 person-years. The incidence of overall cancers and ADCs incidence decreased from 14.5 (95% CI, 0–5.34) and 6.4 (95% CI, 1.7–16.5), respectively in period 1 to 9.80 (95% CI, 6.0–15.2) and 3.0 (95% CI, 1.1–6.4), respectively in period 3, though the differences were not statistically significant. The trend of NADCs incidence remained relatively constant (Table 1). Among the cancers in PWHA, the ratio of NADCs to ADCs increased in the final period (Table 2).

Characteristics of cancers
Baseline characteristics of PWHA were comparable between with and without cancers, except for age and hepatitis B virus (HBV) co-infection (Table 3). Mean age of patients with cancer was 47.9 ± 9.9 years, and 44 (93.6%) were male. About 20% of patients with cancer were co-infected with HBV. Of 48 episodes of cancer, 20 (42%) episodes were ADCs and 28 (58%) were NADCs. Among the 20 ADCs, non-Hodgkin’s lymphoma (5 episodes) and Kaposi’s sarcoma were most common malignancies. Among the 28 NADCs, lung cancer (5 episodes) and hepatocellular carcinoma (5 episodes) were most frequent. The most common malignancies were lung cancer (5 episodes), lymphoma (5 episodes), and breast cancer (5 episodes).

Table 1. Incidence rates of malignancies (cases/1,000 person-years) in HIV-infected patients (95% CI)

| Cancers       | Overall   | 2000–2004 | 2005–2009 | 2010–2014 | P   |
|---------------|-----------|-----------|-----------|-----------|-----|
| ADC           | 4.5 (2.8–7.0) | 6.4 (1.7–16.5) | 6.4 (3.1–11.8) | 3.0 (1.1–6.4) | 0.142 |
| NADC          | 6.3 (4.2–9.1) | 8.1 (2.6–18.8) | 5.8 (2.6–11.0) | 6.9 (3.8–11.6) | 0.917 |
| Total         | 10.8 (8.0–14.3) | 14.5 (0–5.34) | 12.2 (7.3–19.1) | 9.8 (6.0–15.2) | 0.303 |

HIV = human immunodeficiency virus, CI = confidence interval, ADC = AIDS-defining cancer, NADC = non-AIDS-defining cancer.

Table 2. Trend of NADC vs. total cancer ratio in HIV-infected patients (%)

| Patients          | Overall   | 2000–2004 | 2005–2009 | 2010–2014 | P   |
|-------------------|-----------|-----------|-----------|-----------|-----|
| On-HAART patients | 12/15 (80) | 0/0       | 2/3 (66.7) | 10/12 (80) | 0.805 |
| Patients present initially or revisited after LTF | 16/33 (48.5) | 5/9 (55.6) | 7/16 (43.8) | 4/8 (50) | 0.533 |
| Total             | 28/48 (58.3) | 5/9 (55.6) | 9/19 (47.4) | 14/20 (70) | 0.314 |

NADC = non-AIDS-defining cancer, HIV = human immunodeficiency virus, HAART = highly active antiretroviral therapy, LTF = lost to follow-up.
common. However, various types of NADCs such as gastric cancer, colon cancer, and skin cancer were also diagnosed in PWHA (Table 4).

### Comparison between ADC and NADC

The median age of the patients was 47 (interquartile range [IQR], 40.3–55) years in ADCs and 53 (IQR, 47.3–61.8) in NADCs ($P = 0.015$). The median CD4+ T cell counts were higher in NADCs group (ADCs 22 [IQR, 9–274] vs. NADCs 389 [IQR, 144–549.3], $P < 0.001$). Twelve patients (42.9%) among NADCs group and 3 patients (15%) among ADCs group were well adherent to receiving HAART care ($P = 0.040$). Cancers were detected in 2 of 3 patients with ADCs in the early phase of HAART (1.05 and 1.40 years) in spite of good adherence to care. One-year and 5-year survival rates in PWHA with cancer were 39.5% (ADCs 35.7% vs. NADCs 41.7%, $P = 0.717$) and 28.1% (ADCs 30.7% vs. NADCs 26.3%, $P > 0.999$), respectively (Table 5).

### DISCUSSION

Since the introduction of HAART in the mid-1990s, the outcome of PWHA patients who are well adherent to care has improved markedly and the life expectancy has also extended markedly (7,23,24). Before the establishment of HAART, AIDS defining diseases, mainly opportunistic infections, and malignancies were important causes of death. ADCs such as Kaposi’s sarcoma and lymphoma were important causes of death among PWHA (3,7). After the establishment of HAART, AIDS-related deaths gradually decreased and the trends of malignancies in PWHA changed in many countries (9,12,25). The decrease of ADCs and increase of NADCs in PWHA have been described previously in Western countries and in Taiwan (9,16,19,25). Along with the accumulation of experience with HAART, non-AIDS-related deaths, i.e., liver disease and cardiovascular disease, are decreasing (26). However, NADCs are increasing and have become a leading non-AIDS-related cause of death among PWHA (26).

Since there have been no studies to investigate cancer among PWHA in Korea, our findings can provide useful information to improve care among HIV-infected patients.

---

### Table 3. Baseline demographical and clinical characteristics of the enrolled HIV-infected patients

| Characteristics                      | Total (n = 950) | With cancer (n = 47) | Without cancer (n = 749) | $P$  |
|--------------------------------------|----------------|---------------------|--------------------------|------|
| Age, yr                              | 42.4 ± 11.8    | 47.9 ± 9.9          | 42.1 ± 11.8              | < 0.010 |
| Sex (male)                           | 836 (88.0)     | 44 (93.6)           | 792 (87.9)               | 0.690 |
| Mode of transmission                 |                |                     |                          |      |
| Heterosexual                         | 520 (57.3)     | 24 (52.2)           | 496 (57.6)               | 0.468 |
| Homosexual                           | 378 (41.7)     | 21 (45.7)           | 357 (41.5)               | 0.575 |
| IV drug use                          | 12 (1.3)       | 0                   | 12 (1.4)                 | > 0.999 |
| Other blood exposure                 | 4 (0.4)        | 1 (2.2)             | 3 (0.3)                  | 0.188 |
| HBV co-infection                     | 76 (8.9)       | 10 (21.3)           | 66 (8.2)                 | 0.006 |
| HCV co-infection                     | 43 (5.0)       | 4 (8.5)             | 39 (4.8)                 | 0.288 |
| CD4+ T cell count at enrolment, cells/mm² |       |                     |                          |      |
| < 50                                 | 178 (25)       | 12 (27.3)           | 166 (24.9)               | 0.724 |
| 51–200                               | 172 (24.2)     | 7 (15.9)            | 165 (24.7)               | 0.185 |
| 201–349                              | 179 (25.2)     | 16 (35.6)           | 163 (24.4)               | 0.078 |
| > 350                                | 182 (25.6)     | 9 (20.5)            | 173 (25.9)               | 0.420 |
| CDC categories at enrolment          |                |                     |                          |      |
| Category A                           | 396 (53.2)     | 21 (45.7)           | 375 (53.0)               | 0.292 |
| Category B                           | 118 (15.8)     | 11 (23.9)           | 107 (15.3)               | 0.122 |
| Category C                           | 231 (31.0)     | 14 (30.4)           | 217 (31.0)               | 0.931 |

Values are expressed as number (%) or mean ± standard deviation.

HIV = human immunodeficiency virus, HBV = hepatitis B virus, HCV = hepatitis C virus, CDC = Centers for Disease Control and Prevention.

### Table 4. Prevalence of malignancies in 950 study patients, 2000 to 2014

| Malignancies               | Overall (% of patients) | On-HAART patients |
|----------------------------|-------------------------|-------------------|
| Overall malignancies       | 48 (5.05)               | 15 (1.58)         |
| ADCs                       | 20 (2.11)               | 3 (0.32)          |
| Non-Hodgkin’s lymphoma     | 15 (1.58)               | 3 (0.32)          |
| Burkitt’s lymphoma         | 1 (0.11)                | 0                 |
| Diffuse large B-cell lymphoma | 11 (1.16)           | 3 (0.32)          |
| Primary CNS lymphoma       | 3 (0.32)                | 0                 |
| Kaposi’s sarcoma           | 5 (0.53)                | 0                 |
| Cervical cancer            | 0                       | 0                 |
| NADCs                      | 28 (2.95)               | 12 (1.26)         |
| Hodgkin’s disease          | 1 (0.11)                | 1 (0.11)          |
| Anal cancer                | 1 (0.11)                | 1 (0.11)          |
| Acute myeloid leukemia     | 0                       | 0                 |
| Other solid organ tumor    | 26* (2.74)              | 10 (1.05)         |

*Five lung cancers, 5 hepatocellular carcinomas, 4 gastric cancers, 2 colorectal cancers, 2 skin cancers, 2 testicular cancers, 1 vocal cord cancer, 1 thyroid cancer, 1 bladder cancer, 1 angiosarcoma, and 2 metastases with unknown primary site were included.

HAART = highly active antiretroviral therapy, ADCs = AIDS-defining cancers, CNS = central nervous system, NADCs = non-AIDS-defining cancers.

Since the introduction of HAART in the mid-1990s, the outcome of PWHA patients who are well adherent to care has improved markedly and the life expectancy has also extended markedly (7,23,24). Before the establishment of HAART, AIDS defining diseases, mainly opportunistic infections, and malignancies were important causes of death. ADCs such as Kaposi’s sarcoma and lymphoma were important causes of death among PWHA (3,7). After the establishment of HAART, AIDS-related deaths gradually decreased and the trends of malignancies in PWHA changed in many countries (9,12,25). The decrease of ADCs and increase of NADCs in PWHA have been described previously in Western countries and in Taiwan (9,16,19,25). Along with the accumulation of experience with HAART, non-AIDS-related deaths, i.e., liver disease and cardiovascular disease, are decreasing (26). However, NADCs are increasing and have become a leading non-AIDS-related cause of death among PWHA (26). In Korea, 2 previous studies in 2006 and 2009 that investigated trends of cancer in PWHA showed no increase in NADCs and no decrease in ADCs (20,21). Since then, there have been no studies to investigate cancer among PWHA in Korea. Therefore, our findings can provide useful information to improve care among HIV-infected patients.
Firstly, our study showed increasing trends and changing patterns of NADCs among PWHA. In our study, 47 of 950 PWHA patients contracted cancer and the incidence rate of cancer was 10.8/1,000 person-years. There were 8 more cases of NADCs compared to ADCs among the 950 PWHA, and there was a trend of increasing ratio of NADCs development to ADCs development in the last 5 years, though there were no statistically significant differences. The risk of developing NADCs was higher in older patients and on HAART. Lung cancer and hepatocellular carcinoma were followed by gastric cancer, colorectal cancer as the most common NADCs among PWHA in our study. Our data showed a high proportion of hepatocellular carcinoma among PWHA, similar to a previous study, and suggested a high co-infection rate of HIV and HBV in Korean PWHA (27). Interestingly, the proportion of lung cancer among NADCs in our study was markedly increased while the 2 previous studies reported no lung cancer patients among PWHA, and gastric cancer and colorectal cancer were the third and fourth most common cancers (20,21). These findings suggested that the pattern of cancer development among Korean PWHA is similar to that of the general population, along with the extension of life expectancy of PWHA due to the advent of HAART (28). However, the 5-year survival rate of PWHA and NADC was less than 30% and it was markedly lower than the 70.3%, 5-year survival rate of the general Korean population (28). The poor prognosis of cancer patients in PWHA suggested that the cancers were detected at advanced stages. Therefore, cancer screening of PWHA on HAART can be improved, even though the patients have good compliance to HAART.

Secondly, our study showed that ADCs still posed a problem in Korea, especially among late presenters or patients with poor adherence to care. In Western countries and Taiwan, incidence rates of ADCs decreased gradually (9,15,19,25). In our study, the incidence of ADCs decreased slightly in the last 5 years of the study, although it was not significant, and the proportion of ADCs among cancers of PWHA decreased gradually. However, the incidence rate of ADCs was still higher and around 50% of cancers in PWHA were ADCs when patients initially presented with cancer or revisited after loss to follow-up. Among the patients who retained care and continued HAART for longer than 1 year, 3 patients were diagnosed as ADCs (lymphoma). However, 2 patients were diagnosed immediately after 1 year (1.45 year and 1.05 year after HAART initiation). Therefore, our findings support the need to develop strategies to reduce the number of late presenters and to increase retention to care for improving long-term outcomes of PWHA in Korea (29).

This study has some limitations. First, this study is a hospital-based observational study and we estimated the incidence rates using follow-up periods of our hospital. Furthermore, we defined development of cancer if the cases were histologically confirmed. Therefore, the incidence rate could have been underestimated in this study. Second, our study could not investigate the association between smoking and drinking alcohol, and cancer. Third, our study was conducted at a single center in the southeastern region of Korea although our institute is one of the largest HIV and AIDS care centers in southeastern region of Korea. Therefore, our study should be applied to other regions of the country with caution.

In conclusion, the incidence rate of cancer in Korean PWHA was 10.8/1,000 person-year; 4.5 for ADCs vs. 6.3 for NADCs. The 5-year survival of Korean PWHA with cancer was 28.1%. The ratio of NADCs to ADCs in the patients exhibited increasing trends. The incidence rate of ADCs was still higher, especially among late presenters and patients lost to follow-up. Our findings sug-
gest that effective strategies for detecting HIV infection at an early stage, retaining the patients in care after initiating HAART, and screening NADCs with caution to improve the outcomes of cancer among PWHA in Korea are required.

DISCLOSURE

The authors have no potential conflicts of interest to disclose.

AUTHOR CONTRIBUTION

Conceptualization: Lee S, Lee SH. Data curation: Lee S, Lee SH. Formal analysis: Lee S, Lee SH. Funding acquisition: Lee S. Investigation: Lee S, Lee SH. Resources: Lee S, Lee SH. Supervision: Lee S, Lee SH, Lee JE, Kang JS, Lee SG, Chung JS, Kwak IS. Writing - original draft: Lee S. Writing - review & editing: Lee S, Lee SH, Lee JE, Kang JS, Lee SG, Chung JS, Kwak IS.

REFERENCES

1. d'Arminio Monforte A, Sabin CA, Phillips A, Sterne J, May M, Justice A, Dabis F, Grabar S, Ledergerber B, Gill J, et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med 2005; 165: 416-23.
2. Hogg RS, Heath KV, Yip B, Crabt KJ, O'Shaughnessy MV, Schechter MT, Montaner JS. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279: 450-4.
3. Lee SH, Kim KH, Lee SG, Chen DH, Jung DS, Moon CS, Park JY, Chung JS, Kwak IS, Cho GJ. Trends of mortality and cause of death among HIV-infected patients in Korea, 1990–2011. J Korean Med Sci 2013; 28: 67-73.
4. Lee SH, Kim KH, Lee SG, Cho H, Chen DH, Chung JS, Kwak IS, Cho GJ. Causes of death and risk factors for HIV-infected patients receiving antiretroviral therapy in Korea. J Korean Med Sci 2013; 28: 990-7.
5. Mocroft A, Phillips AN, Friis-Moller N, Colebunders R, Johnson AM, Hirshel B, Saint-Marc T, Staub T, Cloetet B, Lundgren JD, et al. Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study. Antivir Ther 2002; 7: 21-30.
6. Palella FJ Jr, Baker RK, Moore MC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD; HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27-34.
7. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuller J, Satten GA, Ashman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
8. Ruxrungtham K, Brown T, Phanuphak P. HIV/AIDS in Asia. Lancet 2004; 364: 69-82.
9. Chen M, Jen I, Chen YH, Lin MW, Bhatia K, Sharp GB, Law MG, Arthur Chen YM. Cancer incidence in a Nationwide HIV/AIDS patient cohort in Taiwan in 1998–2009. J Acquir Immune Defic Syndr 2014; 65: 463-72.
10. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, Grigg R, Hylton T, Pawlish KS, McNeil TS, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123: 187-94.
11. Piketty C, Selinger-Leneman H, Bouvier AM, Belot A, Mary-Krause M, Duvivier C, Bonmarchand M, Abramowiz L, Costagliola D, Grabar S. Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the French hospital database on HIV. J Clin Oncol 2012; 30: 4360-6.
12. Polesel J, Franceschi S, Saligoli B, Crocetti E, Falcini F, Guzzinati S, Vercelli M, Zanetti R, Tagliafuor G, Russo A, et al. Cancer incidence in people with AIDS in Italy. Int J Cancer 2010; 127: 1437-45.
13. Sahasrabudhe VV, Shiels MS, McGlynn KA, Engels EA. The risk of hepatocellular carcinoma among individuals with acquired immunodeficiency syndrome in the United States. Cancer 2012; 118: 6226-33.
14. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92: 1823-30.
15. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeil TS, Scoppa SM, Biggar RJ; HIV/AIDS Cancer Match Study. Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS 2006; 20: 1645-54.
16. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, Holmberg SD, Brooks JT; Adult and Adolescent Spectrum of Disease Project and HIV Outpatient Study Investigators. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med 2008; 148: 728-36.
17. Brock MV, Hooker CM, Engels EA, Moore RD, Gillison ML, Alberg AJ, Keruly JC, Yang SC, Heitmiller RF, Baylin SB, et al. Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr 2006; 43: 47-55.
18. Mitsuyasu RT. Non-AIDS-defining malignancies in HIV. Top HIV Med 2008; 16: 117-21.
19. Franceschi S, Lise M, Clifford GM, Rickenbach M, Levi F, Maspoli M, Boucharly C, Dehler S, Jundt G, Ess S, et al. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer 2010; 103: 416-22.
20. Choe PG, Song JS, Cho JH, Kim SH, Park KH, Bang JH, Park WB, Kim HB, Kim DW, Kim TY, et al. Malignancies in patients with human immunodeficiency virus infection in South Korea. Infect Chemother 2006; 38: 367-73.
21. Seol YM, Song MG, Choi YJ, Lee SH, Kim SI, Chung JS, Kwak IS, Cho GJ, Lee H, Jung DS, et al. Trends in cancer risk among South Korean patients infected with human immunodeficiency virus. Korean J Med 2009; 76: 554-63.
22. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR
23. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. *Lancet* 2008; 372: 293-9.

24. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 2016; 388: 1459-544.

25. Robbins HA, Shiels MS, Pfeiffer RM, Engels EA. Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States. *AIDS* 2014; 28: 881-90.

26. Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. *Lancet* 2014; 384: 241-8.

27. Lee HH, Hong HG, Son JS, Kwon SM, Lim BG, Lee KB, Kim GH. Prevalence of hepatitis B virus and HIV co-infection in Korea. *J Bacteriol Virol* 2016; 46: 283-7.

28. National Cancer Information Center of Korea. Available at www.cancer.gov.kr/mbs/cancer [accessed on 1 December 2016].

29. Kang CR, Bang JH, Cho SI, Kim KN, Lee HJ, Ryu BY, Cho SK, Lee YH, Oh MD, Lee JK. Patients presenting with advanced human immunodeficiency virus disease: epidemiological features by age group. *J Korean Med Sci* 2016; 31: 178-82.